Study of QL Analgesic Response and Extent (SQUARE)
7 juillet 2026 mis à jour par: Duke University
Anterior Versus Posterior Versus Lateral Quadratus Lumborum Block: a Randomized Control Trial in Healthy Volunteers
A total of 14-18 healthy volunteers will be included.
There will be three different procedure days, separated by at least one week.
On each visit, the subjects will receive a QL block, according to the randomization process.
Each volunteer will undergo pre-procedure screening on the first visit.
The blocks will be performed on the same side, by the same anesthesiologist, with at least one week between each block.
An anterior QL block will be administered on one day, a posterior QL block on another, and a lateral QL block on the third.
The order will be randomized, and both the subject and the research team member assessing the block will be blinded.
To compare the dermatomal sensory block distribution, the investigators will use detailed mapping with pinprick, cold, and heat stimuli.
A handheld dynamometric assessment of lower extremity strength.
The testing will be performed 60 to 90 minutes after performance of the blocks.
Aperçu de l'étude
Statut
Pas encore de recrutement
Les conditions
Intervention / Traitement
Description détaillée
Regional anesthesia techniques are widely employed to achieve sensory blockade of the abdominal wall. Among these, the epidural remains the most well-established approach, offering bilateral spread. However, its association with neuraxial complications has led to a decline in its clinical use. In contrast, fascial plane blocks, avoid neuraxial-related risks. The advent of ultrasound-guided blocks has sparked growing interest in novel fascial plane blocks, that can deliver multi-dermatomal with a lower rate of complications.
Three Quadratus Lumborum (QL) blocks are an example of these fascial plane blocks, commonly performed for abdominal and pelvic surgery. Despite their widespread clinical use, no prior studies have directly compared the three techniques in terms of their cutaneous distribution. Additionally, case reports note that lower extremity weakness can sometimes temporarily occur as a result of accidental spread to the lumbar plexus. Thus, this randomized, double-blinded trial aims to investigate the cutaneous distribution of these three blocks in healthy adult volunteers. Lastly, this study will assess the incidence and severity of lower extremity weakness that may occur with each technique. In addition, this study also seeks to investigate the pharmacokinetics (PK) of lidocaine in each technique. The rationale for this lies in the anatomical differences between the blocks. Theoretically, there may be a difference in the anatomical target for these blocks, but the investigators hypothesize that there is no difference in the local anesthetic absorption. Therefore, as the investigators expect similar systemic absorption, the chances of local anesthetic systemic toxicity (LAST) should be equally low, and all blocks should be similarly safe.
Type d'étude
Interventionnel
Inscription (Estimé)
25
Phase
- Phase 4
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Coordonnées de l'étude
- Nom: Brian Mendelson, MD
- Numéro de téléphone: 818-456-7040
- E-mail: brian.mendelson@duke.edu
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Oui
La description
Inclusion Criteria:
- Ability to provide written informed consent
- Ability and willingness to comply with the study procedures and duration requirements
- ASA physical status 1 or 2
- Age ≥ 18 years
- Weight > 70kg
Exclusion Criteria:
- BMI > 35kg.m2
- Use of analgesics within 24 hours before the procedure
- History of thoracic trauma or surgery
- Abdominal deformities or abnormalities that may prevent proper block performance
- Abdominal tattoos in the area of block performance
- Systemic neuromuscular disease
- Contraindications to regional anesthesia (e.g., infection, allergy, challenging sonoanatomy)
- Structures are unable to be visualized by ultrasound
- Pregnancy
- Other known health conditions that would affect the participant's ability to successfully complete the study
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Autre
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
|---|---|
|
Comparateur actif: Lateral Quadratus Lumborum block
Participants receive quadratus lumborum block under ultrasound guidance, with 30mL of 1.5% lidocaine on one visit.
|
For the anterior QL block, a curvilinear probe and nerve stimulator will be used.
Local anesthetic will be deposited anterior to the QL muscle but posterior to the psoas muscle.
A nerve stimulator at 2 Hz frequency, 1.5 mA will be used to aid in identification of intramuscular placement of the needle.
Local anesthetic will only be deposited if no twitch is seen in either the QL or psoas muscle with an appropriate circuit formed.
For the posterior QL block, a linear or curvilinear probe will be used, at the discretion of the anesthesiologist.
Local anesthetic will be deposited posterior to the QL muscle such that anterior depression of the muscle is seen.
For the lateral QL block, local anesthetic will be deposited lateral to the QL muscle.
|
|
Expérimental: Anterior Quadratus Lumborum Block
Participants receive anterior quadratus lumborum block under ultrasound guidance, with 30mL of 1.5% lidocaine on one visit.
|
For the anterior QL block, a curvilinear probe and nerve stimulator will be used.
Local anesthetic will be deposited anterior to the QL muscle but posterior to the psoas muscle.
A nerve stimulator at 2 Hz frequency, 1.5 mA will be used to aid in identification of intramuscular placement of the needle.
Local anesthetic will only be deposited if no twitch is seen in either the QL or psoas muscle with an appropriate circuit formed.
For the posterior QL block, a linear or curvilinear probe will be used, at the discretion of the anesthesiologist.
Local anesthetic will be deposited posterior to the QL muscle such that anterior depression of the muscle is seen.
For the lateral QL block, local anesthetic will be deposited lateral to the QL muscle.
|
|
Expérimental: Posterior Quadratus Lumborum Block
Participants receive posterior quadratus lumborum block under ultrasound guidance, with 30mL of 1.5% lidocaine on one visit.
|
For the anterior QL block, a curvilinear probe and nerve stimulator will be used.
Local anesthetic will be deposited anterior to the QL muscle but posterior to the psoas muscle.
A nerve stimulator at 2 Hz frequency, 1.5 mA will be used to aid in identification of intramuscular placement of the needle.
Local anesthetic will only be deposited if no twitch is seen in either the QL or psoas muscle with an appropriate circuit formed.
For the posterior QL block, a linear or curvilinear probe will be used, at the discretion of the anesthesiologist.
Local anesthetic will be deposited posterior to the QL muscle such that anterior depression of the muscle is seen.
For the lateral QL block, local anesthetic will be deposited lateral to the QL muscle.
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with blocked areas as measured by skin temperature discrimination
Délai: 60 to 90 minutes post-block
|
Skin temperature assessment using gloved ice on the chest wall, to discriminate blocked vs unblock areas.
|
60 to 90 minutes post-block
|
|
Number of participants with blocked areas as measured by mechanical discrimination
Délai: 60 to 90 minutes post-block
|
Mechanical assessment using a neuropin (pinprick) on the chest wall, to discriminate blocked vs unblock areas.
|
60 to 90 minutes post-block
|
|
Blocked area as measured by cutaneous distribution mapping
Délai: 60 to 90 minutes post-block
|
Mapping the blocked area (using the previous temperature and mechanical assessments, demarcating lines on the skin) to calculate the area blocked.
|
60 to 90 minutes post-block
|
Mesures de résultats secondaires
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Skin temperature of the chest wall
Délai: 60 to 90 minutes post-block
|
Infrared camera will assess skin temperature of the chest wall.
|
60 to 90 minutes post-block
|
|
Blocked area as measured by nociceptive discrimination
Délai: 60 to 90 minutes post-block
|
Nociceptive stimuli will be delivered using controlled heat to discriminate blocked versus unblocked areas on the chest wall.
|
60 to 90 minutes post-block
|
|
Lidocaine systemic absorption
Délai: 0, 30, 60, 120, and 240 minutes after lidocaine administration
|
Calculate lidocaine systemic absorption (Cmax).
|
0, 30, 60, 120, and 240 minutes after lidocaine administration
|
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Number of participants with block-related Adverse Events
Délai: End of study (2 days post blocks)
|
Any block-related adverse events will be recorded.
|
End of study (2 days post blocks)
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Parrainer
Les enquêteurs
- Chercheur principal: Brian Mendelson, MD, Duke University
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude (Estimé)
1 janvier 2027
Achèvement primaire (Estimé)
1 avril 2027
Achèvement de l'étude (Estimé)
1 avril 2027
Dates d'inscription aux études
Première soumission
29 avril 2026
Première soumission répondant aux critères de contrôle qualité
29 avril 2026
Première publication (Réel)
5 mai 2026
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
8 juillet 2026
Dernière mise à jour soumise répondant aux critères de contrôle qualité
7 juillet 2026
Dernière vérification
1 avril 2026
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- Pro00118381
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
NON
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Oui
Étudie un produit d'appareil réglementé par la FDA américaine
Non
produit fabriqué et exporté des États-Unis.
Non
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .